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WA This study was d 
use of continuoMs 
tieats who were 
received an initial bolus of heparin and then were randomized 
during tbe procedure to receive either no additional bepsrin 
therapy or an adjusted 24-b infusion. On tbe basis of specific 
criteria, additional beparin was not withheld if placredural results 
suggested an incmsed risk for complications. 
Cardiac catheterizati:>n and percutaneous transluminal coro- 
nary angioplasty remain integral components in the manage- 
ment of patients with symptomatic oronary artery disease. 
Outpatient diagnostic cardiac catheterization is now an estab- 
lished technique and has been shown by many investigators 
(l-6) to be safe and cost-effective. Similarly, technical ad- 
vances and greater operator experience have improved the 
safety and success of coronary angioplasty. A recent study at 
our institution (7) demonstrated that up to two thirds of 
selected patients undergoing elective angioplasty could be 
stratified by risk and safely discharged within 24 h of the 
procedure. 
The duration of continuous heprrin therapy significantly 
influenced the length of hospital stay by preventing early 
sheath removal. However, the prescribed duration and inten- 
sity of routine anticoagulant herapy to prevent acute vessel 
occlusion after uncomplicated coronary angioplasty varies 
widely among institutions and among angiographers (8-1 I), 
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nt risk. Earlier discba 
often as a matter of convenience. Prolonged continuous hep- 
arin infusion increases the incidence of bleeding, may not 
decrease the frequency of abrupt vessel reclosure and has no 
effect on the rate of late restenosis (12). For scientific and 
economic reasons, prospective evaluation of continuous pro- 
longed heparin therapy versus abbreviated heparin therapy 
with early sheath removal fter uncomplicated coronary angio- 
plasty is necessary. 
Patient selection and entry criteria. Between July 1989 and 
February 1991 all patients scheduled for elective coronary 
angtoplasty were prospectively evaluated for study enrollment. 
Ail patients with documented stable angina pectoris were 
screened 2 days in advance of the procedure by a cardiologist 
and a nurse clinician, an informed consent was obtained 
according to Institutional eview Board guidelines. A com- 
plete blood count, electrocardiogram (ECG), biochemistry 
screen and coagulation profile were obtained at ihat time. All 
patients were routinely prescribed aspirin (325 mg daily) and a 
calcium channel antagonist ?ominimize vascular complications 
(13). 
Enrollment was not restricted because of advanced age, 
presence of multivessel or multilesion coronary artery disease, 
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eprin 
Nitrates, Ca antagonist 
ipre 1. Study algorithm. ASA = aspirin; Ca = calcium channel; 
CAB6 = coronary artery hypnss graft surgq; PTCA = percutaneous 
Ir~~~S~~lm~~ij~ COKMIil~ a~giOplilS~. 
previous coronary bypass surjp=y or revious coronary angio- 
plasty. patients were exclu ed if i’ecent myocardial ~n~~~r~ti~~~, 
~~~COn~~enS~~ted left Vel~t~i~~~lilr dyS tion, valwlar heart 
disease, coagulopathy, s~gliilica~~t r function or unstable 
aag~~~~ y l~t~rn~ WX present. 
~~~a~ica~ or laser at~~erecto~~y were also excl 
patients with totally occluded ta 
patients reported to a previ- 
cardiac unit established for intermedi- 
ate level postangioplasty nursing care (7). Patients were admit- 
ted 1 to 2 h before the procedure. The unit is equipped with 
hemodynamic and KG telemetry monitoring. Preprinted 
order sheets were used to standardize patient care and mini- 
mize protocol deviations. The unit was administratively con- 
sidered an outpatient facility but atients could be reassigned 
to inpatient status out need for bed transfers. Angioplasty 
procedures were p rmed only when a backup cardiovascu- 
lar surgical team was available. 
?ro Randomization was performed by 
means es. Percutaneous 7F or 8F vascular 
sheaths were inserted by direct femoral artery approach. 
Alternatively, a direct arteriotomy was performed when bra- 
chial artery access was required. Every patient received a 
initial bolus of 10,000 to 15,000 U of intravenous heparin an 
5,000 additional U every 60 min during the procedure. Intra- 
coronary nitroglycerin (200 pg) was administered before the 
lesion was crossed, and the dose was repeated when necessary. 
Percutaneous transluminal coronary angioplasty was per- 
formed by standard techniques (114,15). Transvenous pacing 
wires and nonionic contrast medium were not routinely used. 
Angiographic results were reviewed by digital or videotape 
replay, or both; cineangiograms were processed and available 
for detailed review by the operator whenever necessary befc re 
completion of the procedure. 
Randomization. All patients with favorable angiop!asty 
results were assigned to the abbreviated or the prolonged 
heparin infusion study arm (Fig. I). Neither the patient nor the 
higil risk a~~g~~gra~b~c ab~~~~a~~t~~s (complex or extensive 
arterial dissection or intracoro~a~ thrombus formation) fern 
excluded (7,14). These patients were directed to extended 
SePIatiOn and managen~ent. Other contrdindica- 
tions to heparin random~zat~oi~ ~c~~ded abrupt vessef closure, 
need for emergency bypass urgery, use of thrombolytic tber- 
ension or bleeding. 
tients were returned to the 
tely after coronary angio- 
m~~ist~tion of aspirin, intravenous nitroglycerin and 
~nnel antagonists was routinelv continued, Patients 
bad the vascular sheath 
removed within 3 to 4 h of the procedure unless the activated 
clotthrg time exceeded 150 s. Patients assigned to prolonged 
n received a continuous heparin infusion 
for 24 b. The dose rate of h 
activated clotting time tev 
to a standard sliding scale employing serial 
activated clotting time measurements a  4- to 6-b intervals. All 
sheaths were removed manually by trained n~nphys~~~a~ per- 
sonnel or by a cardiology fellow. In all cases, arnb~~at~~~~ was 
encouraged after 6 h of strict bed rest and inguinal compres- 
sion by a lO-lb (4.5 kg) sandbag. The inguinal area was 
inspected and the patient was given discharge instructions, 
Patiei..s were contacted by a nurse clinician 1 to 2 days after 
discharge to assess for delayed vascular complications and 
symptom status. 411 participating physicians were required to 
report any related out-of-hospital complications. 
r:istorical details, clinical data and the 
results of coronary angioplasty were prospectively recorde 
The length of hospital stay (total hours after coronary angio- 
plasty) and reasons for transfer to an inpatient unit were 
recorded. Ilf a complication or contraindication to heparin 
randomization was identified, the patient’s location and the 
time in relation to coronary angioplasty were noted. Compli- 
cations including death, acute myocardial infarction, need for 
emergency bypass surgery, acute coronary occlusion syndrome 
and unstable angina (with or without EC6 changes) were 
considered major complications under all circumstances. 
Other clinical complications included arrhythmias, excessive 
local bleeding or hematoma formation, need for blood trans- 
fusion and need for subsequent reevaluation or readmission. 
A computer-generated list of complete patient charges was 
obtained from the hospital financial services department. The 
total hospital charge for each patient was recorded. 
Statist& The chi-square and Fisher exact est were used 
to determine differences between treatment groups. Data are 
expressed as mean value I? SD. Sample size was modeled after 
previous studies of early hospital discharge after dCUte mYo- 
cardial infarction (17) and elective cardiac catheterization (4). 
Sample size calculations based on end point analysis were not 
prospectively performed. 
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Table 1. Baseline Demcgaphics 
Abbrebiatcd 
Hrparin Thernpy 
Ill = 145) 
24-h 
Heparin Therapy 
(n = 13Y) 
49 (YO MI z IO 61 -t IO 
Gender (% male) 70% 71si 
Previous MI ‘WL 3El’i 
Prcrious PTCA 3YG 284 
Previous CABG 14% 12% 
Angina cl;~ss 2.4 r 0.Y 2.5 2 1.0 
Diabctcs If,‘> 195 
Hypertension 3sq 375 
Smoking 14’ i 175 
Oata prcscnlcd itrc mo;m v;~Ius ! SD (jr pcrccnt of pilticnt group. No 
rlikrcnccs bclwccfl groups wcrc signilkmt. CAUCi : blWtlflil~ artcry byp;~bs 
grilft aurgcry: MI = mytric-dial infkctinn; P’K‘A - p~rwI;IIlctws tr;mslumin;~l 
coronii~ imgiopl;lhty. 
@Stnki 
Study patients. During the study period a total of I.611 
outpatients were cvshuatcd as potential study candidates. and 
400 patients (2%) consented to enrollment into the study. 
One hundred sixteen patients were excluded after cnroilmcnt 
tither because they did not undergo anticipated concurrent 
angioplasty during diagnostic ardiac catheterization or because 
attempted balloon dilution could not be performed (Fig. 2). 
Clinical characteristics. The baseline demographic charac- 
teristics of thcJe patients arc shown in Table I. Thcrc were no 
statistically significant ditferences between the treatment 
groups. The prolonged and abbreviated heparin therapy 
groups were also similar with respect o preprocedurc adverse 
prognostic risk factors. Of the 284 patients who undcnvLnt 
balloon dilation, 139 were randomized to receive 24 h of 
continuous heparin therapy and 145 to reccivc no additional 
heparin. A total of 3tiX stenoscs were dihttcd (I.,?lpaticnt) with 
210 patient? undergoing single-vessel and 76 patients multives- b” 
sel procwdurcs. 
Outcome.. On the basis of angiographic findings assessed 
during the procedure. 4h patients were excluded after random- 
ization in the catheterization laboratoty and were triaged to 
inpatient management (Fig. 2). Excluded patients were evenly 
distributed between the two heparin therapy groups. All of the 
rcmaininy 238 patients completed :he study. Of the 46 ex- 
eluded, II patients developed evidence for acute myocardial 
infarction. 2 received intraaortic balloon pump support and 2 
required cardiopulmonary resuscitation. Two of these 46 pa- 
tients required coronary bypass surgery and none of the 16 
died. Additional reaborlh for angiographic exclusion are listed 
in Table 2. 
Minor complications. Among the 1 IS patients randomized 
to abbreviated heparin therapy, 30 underwent additional ob- 
servation because of physician preference related to minor 
postprodure complications. Reasons included procedural 
comple~ty (n = 91, “hazy” or “irregular” results (n = 8) 
ventricular arrhythmias (n = 2). atypical chest pain (n = 2), 
400 Enrolled 
t- 
116 No PTCA 
284 I’TCA 
139 H+arin 245 No Mepain 
gastric bleeding (I~ = i ), dyC allergy (II = 1) and guide 
catheter-induced dissection (n = I ). The rcl~ili~~il~~ six pa- 
tients were observed solely because of patient or physician 
rcqucst. Twenty-seven of these patients received additional 
intravenous heparin for a median period of 13 h. lnguinal 
hematonm formation and episodes of local bleeding W~XC 
significantly more common in the group receiving 24-h atatico- 
agulation. Data reflecting treatment received are shown in 
Table 3. 
Mqjor comrplications. One major event occurred 2 h after 
angioplasty in the abbreviated heparin therapy group. The 
patient developed acute vessel occlusion syndrome and despite 
SUCCCSSfUl Kpeilt coronary :UIgiOpliISty. ii !lW-Q WBVe nlyocar- 
dial infarction dcvcloped (Table 3). 1 here were no other major 
cardiac complications in either group. No delayed complica- 
tions were rcportcd by the participating physicians, 
Mospital utilization. The average length of hospital stay for 
[ill patients randomized to the abbreviated heparin therapy 
group was 23 ?I I I h in contrast to the significantly longer stay 
(42 ?I 24 h, p < 0.W) in the prolonged heparin infusion 
group. Eighty-five patients (72%) in the abbreviated therapy 
group were discharged within 24 h and 22% were dkharged 
within 14 h of the procedure (Fig. 3). The mean hospital charge 
was $6,093 + $1.772 for those receiving abbreviated heparin 
therapy versus $7,463 
infusion (p < O.oOl). 
t 1,782 for those receiving 24-h heparin 
Table 2. Aagiclgraphic Ewdusbns 
Dissectiou 
Thrombolytic thcropy 
Abrupt wsscl closure 
Total occlusions 
Inlrxoronary thrombus 
Emergeq CABG 
Left main coronary artery spasm 
Total 
CABG = coronary artery bypass graft surgery. 
equipment design and procedural techniques, less scientific 
attention has been applied to improving or streamlining man- 
agement strategies after the procedure (7.X,1 I). Outpatient 
diagnostic cardiac catheterization has already become widely 
accepted at most institutions. The incidence of observed 
complications in outpatients is equal to or less than that for 
procedures previously performed on an inpatient basis (l-5). 
Similarly, outpatient peripheral angioplasty has gained favor 
and has been shown fo be safe ( 1X,19). On the basis of data 
from our pitot stady (7), we expected that a similar approach 
with carefully selected patients after an uncomplicated coro- 
nary angioplasty procedure could bc safe. clini;ul!} practical 
and less expensive. 
~a~~ern~ safety and risk &rat ation. The baseline clinical 
characteristics in our study gro are similar to those of the 
eart, Lung, and Blood Institute Registry Cohort, 
Emory University, Cleveland Clinic and other larger study 
ulations (9.?~,~~,21~. Nevertheless. we emphasize that 
patient selection and lriape aigorithms developed for the 
currcm study were de~jbe~~tcly conservative and always f+ 
vored in-hospital management when clinical unccrtaintics 
aro~c. Only patients with a low risk profile and uncomplicated 
coronary anatomy were considered, and only patients with 
stable angiographic appearance after coronary angioplasty 
were studied. Patients presenting with the specific adverse 
prognostic risk factors identified in the Methods section were 
excluded from the siUdy and preferentially directed to inpa- 
tient management because of their higher rate of acute procc- 
dural failuae (15,2,23). Conversely. scheduled catheterization 
with possible concurrent angioplasty was not specifically cx- 
eluded hy oUr protocol because others (24) haue shown 
combined procedures to be safe and efkcrivc. 
Cathctcrization lahimtniy ttkge criteria focused primarily 
on immcdiatc procedural rt’sulls. For this reason predilation 
angiographic morphology as such was not Used to cvaluatc 
cligihility for study. Important predictors of delayed complic;i- 
tions arc provided by postproccdurc angiographic and clinical 
findings (22,25). Moreover, it h;s been shown (15,17) that a 
significant residual stenosis or a complex intimal dissection 
increases the risk of abrupt closure. The prcscnce of an 
intraluminal thrombus has also been associated with a marked 
increase in acute complications (33,2h). We believe that the 
present study is the lirst to attempt to use these data in a 
prospective fashion to stratify patients hy risk after coronary 
angiopiasty. The benign course for the 2X4 patients emolled in 
either treatment arm suggests that clinically low risk C~SCS can 
be prospectively d&cd. 
~~m~~~ca~~u~s~ Despite the excclicnt imined& angio- 
graphic results of coronary angioplasty, 2V to 45 of palicnls 
expcriencc sudden vessel occlusion uncxpecacdly. IJp 1~ 80% 
of acute coronary complications occur before the patient 
leaves the catheterization laboratory and 90% of comp?ications 
occur within 6 h after the procedure (9,10,20,22,25). Moreover. 
nearly two thirds of these patients with initially “uncomplicat- 
ed” results will demonstrate hypotension, persistent EiG 
l:igure 3. Duration of hospital stay for 73X patients random- E 
ized before angioplasty to receive either an adjusted 24-h 3 
ileparin infusion (solid bars) or saline solution (open bars) 8 
after a successful procedure. 
14-24 24-48 
Length of Stay (hours) 
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changes or prolonged chest pain during the balloon procedure. 
?he rare instanw cf delayed acute occlusion after a totally 
edure most often occurs shortly after dis- 
arin therapy (27). As a matter of practice, 
delayed occlusion wouId necessarily have 
tions before hospital discharge in the cur- 
rent study, because ambulation occurs at least 8 to 10 h after 
normalization of M4md coagulatien. Whether continuous pro- 
longed intravenom heparin administration reduces the inci- 
dence of subacute coronary complications cannot be answered 
by this stu er, Ellis et al. (12) have &own that a 
similar stra ungcd heparin infusion after early sheath 
removal-does not decrease the frequency of abrupt vessel 
ClOSUtZ. 
Our study design also prevents rnea~i~~f~~i assessment of 
any adverse cvenes that developed 3 to 7 days after the 
procedure, although none were reported. ~x~ri~nce suggests 
that Ihe risk of unforeseen ahtupt vessel closure occurring 23 
days after an ~nco~~piic~~ted angioplasty procedure is cx- 
tremely low (7). In addition, recent A~~~AHA Task Force 
guidelines (23) indicate that patients can be safely discharged 
within 24 lo 48 h after an uncomplicated angioplasty proce- 
dure. 
Bleeding complications related to vascular access were 
signiticantly more frequent in the group with prolonged hep 
arin infusion. Despite strict guidelines, hcparin was prcma- 
surety discontinued because of bleeding in 10% of patients. 
Similarly, Ellis et al. (12) have shown that an 18- to 24-h 
hepurin infusion, despite early removal of the vascular sheaths 
after angioptasty, doubles the incidence of significant bleeding 
to ~8%. The two major factors that have been shown to affect 
local hemostasis are vascular sheath size and the duration of 
anticoagulation (28-30). (4~ data are consistent with the 
latter observation. Potential late vascular sequeluc such as 
pseudoaneurysm and arteriovenous Rstula formation may not 
have been identified in the current study because of the brief 
foliow~up period. The incidence of such complicatiots ranges 
between O.S% 10 LO% and the diagnosis is usually delayed for 
several days to weeks (29). 
I[llost saviags. As P result of early sheath removal and 
ambulation. patients who did not receive a prolonged heparin 
infusion were often ready for discharge within 12 h of the 
angioplasty procedure. Some patients were observed for a 
slightly longer period. usually to avoid late night or predawn 
discharge. Nonetheless, early ambulation and discharge were 
significantly more economic. By reducing hospital utilization, 
total charges were reduced by nearly $I,rlOO/paticnt in the 
abbreviated heparin therapy group, This finding parallels 
outpatient diagnostic cardiac catheterization charge savings 
that have been reported to range from $580 to $933 (4,3l). on 
the basis of our study enrollment rate, 25% (400 of 1,611) of 
the patients undergoing the estimated 300,000 coronat)l angio- 
Plasty procedures performed annually in the U&cd States 
would be eligible for consideration and three fourths of these 
Patients couid be successfully treated. The health care cost 
savings yielded by this strategy could approach $100 million/ 
year. 
Study limitations. It must be emphasized that a stable, low 
risk group of patients with acceptable angiographic results 
after coronary angioplasty were randomized. These findings 
cannot be extrapolated to patients with an acute ischemic 
syndrome or unstable angiographic results. Because c%f the 
need for informed consent, tients were enrolled before the 
catheterization procedure. arty-sir patients 
quently excluded and operator bias may have in 
decision. Finally. the s 
proof of safety. 
events (death, r emergency bypass 
surgery) occurred in 6.7% of patic~ts in 
have sufficient power to detect a 50% increas 
would have req~ircd a study of 800 patients. 
adverse events (I of 238, 0.4%) was 
thousands of pat&&s would have been re 
power this end point. 
ConcUus~~~s. Our study su ion 
of intravenous administration ath 
removal after uncomplicated coronary angiopiasty is conve- 
nient asd reduces speeding co~~~~icatio~s without increasing 
patient risk. Early discharge and signifi nt cost savings are 
possible if prudent patient selection an Consecutive ttjqj~ 
criteria are observed. As experience increases, expanding the 
protocol to include patients with reduced left ventricular 
function or concurrent medical illnesses may be feasible. 
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